OBJECTIVES: This study analysed survival and long-term outcomes of heart transplantation in patients aged 60 years and older. We also analysed the impact of a national graft allocation priority [Super Emergency (SE)] and compared survival with younger patients in our centres and in France.
INTRODUCTION
Due to the ageing population and improvements in medical therapy, the number of patients suffering from heart failure is constantly increasing, and consequently, more and more patients may become candidates for heart transplantation. However, therapeutic opportunities for those of advanced age are challenged by a critical shortage of donor hearts as well as ethical issues [1] , emphasizing the growing importance of adequate patient selection. Because of associated comorbidities, elderly patients may also be at a higher risk of complications after heart transplantation, which may partly explain the association between increasing age and poorer survival [2] . However, previous studies [3] reported encouraging survival rates in the elderly people.
No recent data have been published regarding long-term survival and outcomes in elderly patients who underwent heart transplantation in Europe. The primary objective of this retrospective and multicentre study was to analyse the survival and detailed outcomes of heart transplantation in patients aged 60 years and older during a 2-decade period . The secondary objectives were to compare outcomes between the first and second decade and to analyse the impact of a graft allocation priority that was initiated in 2004 [entitled 'super emergency' (SE)], which gave the most severe patients a high national priority during a specific period. For the last objective, the French Biomedicine Agency database was used to compare survival between older and younger recipients in our centres and in France.
METHODS

Study design and patient population
We conducted a retrospective analysis in patients 60 years of age and older who underwent heart transplantation at 3 tertiary French centres (Nantes, Rennes and Tours) between 1 January 1994 and 31 December 2013 with a minimal follow-up of 1 year.
With the help of the French Biomedicine Agency:
• In our centres, baseline characteristics were compared between younger and older recipients using Cristal (national registry of patients registered on the French waiting list).
• Survival of the entire population (including combined transplantation) was also compared in our centres and in France.
Data extraction
Medical records were obtained from the archives in the respective centres and completed with Cristal. Extensive data from donors were also available.
Definition of primary end points
Cardiac allograft vasculopathy and primary graft dysfunction were defined according to ISHLT statements published in 2010 [4] and 2014 [5] . Acute rejection episodes were documented using endomyocardial biopsies and graded according to the 1990 ISHLT classification or according to the revised classification from 2005 [6] . Before 2005, rejection was considered at Grade 2 or greater; after 2005, we considered rejection as Grade 2R (or greater) or Grade 1R when it required intravenous treatment or hospitalization or was responsible for allograft dysfunction. Post-transplant infections were defined by the presence of positive cultures in the blood or any infection requiring intravenous antibiotics or patient hospitalization. Specific infections in the setting of immunosuppression were also considered.
Malignancies were documented using confirmed pathological tissue analysis (histological examination). Vascular complications were defined as a peripheral vascular disease requiring surgical or endovascular management, a cerebral ischaemic stroke or an acute coronary syndrome. Chronic kidney disease was defined according to Kidney Disease Outcomes Quality Initiative guidelines.
The clinical status of the patients at transplantation was defined following the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS [7] ).
Patient selection process
Our older recipients underwent stringent and careful selection. Most of the patients with significant renal impairment, peripheral vascular disease, pulmonary disease, malignancy or uncontrolled cardiovascular risk factor were excluded from transplantation. Compliance and physiological age were also taken into account.
Donor acceptance criteria and graft procurement
The French Biomedicine Agency is the national agency that regulates and evaluates transplantation activities. Until 2004, cardiac graft allocation in France was centre based; donor acceptance was dependent on the decision of each medical team. Patients in the most critical condition could be allocated a graft according to regional priority between our 3 centres.
In 2004, 2 national priority lists were added to the French cardiac graft allocation system, which enabled some patients to obtain nationwide priority for a limited duration [2 consecutive periods of 48 h for super emergency type 1 (SE1); 8 days for super-emergency type 2 (SE2)]. Patients were eligible for SE1 status if they were hospitalized in intensive care units for end-stage heart failure requiring inotropes for at least 48 h (> _10 mg/kg/min for dobutamine, > _0.1 mg/kg/min for epinephrine or norepinephrine or > _2 inotropes) and/or were receiving extracorporeal membrane oxygenation or another type of short-term circulatory support. SE2 status applied to patients on mechanical cardiac support presenting with device-induced complications (uncontrolled device infection, pump thrombosis, embolism or recurrent ventricular arrhythmias). Since 2013, a creatinine clearance > _40 ml/min/1.73 m 2 using the modification of diet in renal disease (MDRD) formula has also been required to apply for the high emergency list.
Each team can request a recipient to be placed on these priority lists; however, acceptance and subsequent inscription depend on the decision of medical experts named by the French Biomedicine Agency. To ensure appropriate and equitable decisions, these experts are independent from the centres requesting the priority.
Elderly patients awaiting heart transplantation were placed on a list similar to that for the younger patients. Marginal donors were occasionally used in our centres depending on the patient's condition and associated comorbidities. Acceptance of the donor's graft was dependent on the physician in charge of the patient.
Immunosuppressive treatment
The choice of immunosuppressive treatment was similar in all centres. Immunosuppressive therapy consisted of induction with either anti-thymocyte globulin or in rare cases with chimeric monoclonal antibody blocking IL-2Ra. Maintenance therapy was composed of a calcineurin inhibitor in association with azathioprine, which was progressively replaced by mycophenolate mofetil. Steroids were progressively tapered postoperatively, and most of the patients received a long-term low dose. In some patients with chronic kidney disease, vascular complications or skin cancers, treatment with the mammalian target of rapamycin (Everolimus) could be introduced.
Postoperative course
To compare the postoperative course of our elderly patients, we used a period-matched control group from a younger [8] cohort in one of our centres (Rennes University).
Statistical analysis
Continuous variables are reported as means ± standard deviations, and categorical variables are reported as frequencies. Characteristics were compared using the v 2 test or Fisher's exact test for categorical variables and the 2-tailed t-test for continuous variables. Survival rates were calculated with a Kaplan-Meier product-limit estimator using the log-rank test to compare the groups. Values of P < _ 0.05 (2-tailed test) were considered statistically significant. Independent factors for all-cause mortality were established using the Cox proportional hazards regression method after exploratory analysis of recipient and donor variables. Significant variables (P < _ 0.20) in the univariate analysis or clinically pertinent variables were identified and included in the multivariate analysis. P-values <0.05 were considered statistically significant. The statistical analysis was performed using SAS 9.3 (SASV R Institute, Inc., Cary, NC, USA).
RESULTS
General characteristics of the population
A total of 212 patients aged between 60 and 68 years (mean age of 62.8 ± 1.9 years) underwent predominantly orthotopic bicaval heart transplantation between 1 January 1994 and 31 December 2013 in our centres (full characteristics in Table 1 ). Retransplantation was performed in only 4 patients. The population was characterized by a predominance of males (80.7%) and ischaemic cardiomyopathy (50%). At the time of transplantation, INTERMACS score of our population was 4.55 ± 1.70, with 7% of patients on mechanical ventilation and 11.3% under mechanical circulatory support.
When comparing baseline characteristics between younger and older recipients, we noticed that older recipients had more ischaemic cardiomyopathy and were more often called from home at transplantation. Other characteristics were comparable including donor age (Supplementary Material, Table S1 ). Donors had a mean age of 38.5 ± 13.2 years; additional characteristics of the donors are provided in Table 2 .
Characteristics of the surgery and postoperative complications are presented in Table 3 . The mean intensive care unit stay was 
Survival and outcomes
Postoperative course was similar between younger and older recipients (Supplementary Material, Table S2 ). A total of 84 patients died during the study period and the survival analysis (shown in Fig. 1 ) showed 1-and 5-year survival rates of 84.89 ± 2.46% and 78.19 ± 2.94%., respectively Survival-free from major complications can be found in Table 4 and Fig. 2 . The primary cause of infections in our population was cytomegalovirus (CMV) and malignancies were dominated by skin cancers. However, mortality was dominated by non-skin cancers (Supplementary Material, Table S3 ) that highly impacted survival (P = 0.0061). Twenty-two patients required chronic haemodialysis.
Predictors of survival
Long-term complications significantly associated with impaired survival were vascular complications and malignancies. Interestingly, recipient and donor ages were not associated with survival.
In the multivariate analysis, a history of ischaemic cardiomyopathy conferred impaired survival with a hazard ratio (HR) of 4.1. Some postoperative complications also significantly impacted survival, such as mechanical circulatory support after transplantation (HR = 4.2), postoperative haemodialysis (HR = 9.5) and longer intensive care unit stay (HR = 7.2).
Evolution of survival and outcomes over 2 decades
Survival in our population was not significantly different (P = 0.53) between the first and second decades of the study (Fig. 1) ; however, survival-free from cardiac graft vasculopathy was lower in the second decade. In the second decade (Table 1) , patients more frequently required mechanical ventilation (11.3% vs 2.1%, P < 0.05) and mechanical circulatory support (18.8% vs 3.2%, P < 0.05). Consequently, postoperative course and complications were more prevalent with longer hospitalizations. Donors (Table 2) were significantly older in the second decade (41.4 vs 34.9 years old, P < 0.05) and had more cardiovascular risk factors.
Super emergency group
INTERMACS score was lower in the SE group (2.74 ± 0.97) and those patients were more frequently under mechanical ventilation (30.7%), mechanical circulatory support (47.4%) or inotropes. This critical condition was responsible for a significant impairment of renal function and postoperative complications were more likely to occur. Consequently, hospitalizations were longer, with a mean length of stay of 59.0 ± 38.4 days. Donors were similar to the other groups despite an increased incidence of cardiovascular risk factors. Long-term survival was not affected by the new graft allocation priority, but patients were more likely to be on chronic haemodialysis in this group (Fig. 2) .
Comparison with younger patients
Survival was significantly impaired in older patients in our centres (P = 0.004) and in France (P < 0.001; Fig. 3 ). Survival differences between younger and older recipients appeared to be inferior in our centres compared with France, with differences of 4.1% at 1 year, 3% at 5 years and 4.2% at 10 years vs 8.9%, 8.2% and 10.9%, respectively.
DISCUSSION
The primary finding of our long-term multicentre study is that survival after heart transplantation in selected elderly patients is encouraging, with 1-, 5-and 10-year survival rates of 83.2%, 77.4% and 63.8%, respectively (when including combined transplantation). Interestingly, the results obtained in our elderly patients were superior to those in younger patients transplanted in France during the same period. Malignancy was the main cause of death in our population. Most of the available literature in older patients confirms favourable outcomes in recipients older than 60 years. In the recent ISHLT [2] registry, survival in the contemporary cohort (transplantation between January 2006 and June 2012) of patients aged between 60 and 69 years were comparable to ours, with 1-and 5-year survival rates of 82.2% and 70.5%, respectively.
Our recipients were carefully selected with a low proportion of cardiovascular risk factors. Stringent and rigorous follow-up was also particularly important in our elderly population, in whom complications are potentially more severe because of age and associated comorbidities. We hypothesize that the quality of the follow-up in our centres significantly impacted survival rates; this was confirmed in one of our previous publications [9] .
Our satisfactory survival results may also be explained by the fact we did not systematically use older or marginal donors. Notably, the mean age of our donors was 38.5 years over a 2-decade period, whereas their mean age was 42.9 years in 2013 in France [10] .
Postoperative course
Most of the literature remains scarce and contradictory regarding short-term complications. Moreover, international registries may be biased by significant missing data regarding the postoperative course, which complicates a direct comparison with our cohort. A detailed analysis [3] of the UNOS database, which included 14 401 recipients, revealed that patients older than 60 years had a slightly longer hospital stay and more postoperative infections. However, a comparison with younger patients included in a recently published study [8] in one of our centres (Rennes Hospital) revealed that our elderly had an acceptable postoperative course.
Long-term outcomes
The long-term outcomes of our population were similar to those of previously published studies assessing the elderly. The survival-free from rejection at 1 year was comparable to those from the ISHLT registry [2] and a publication by Zuckermann et al. [11] (74.4% and 83.5%, respectively). Malignancy outcomes were in accordance with the 60-to 69-year-old population from the ISHLT registry. Survival-free from cardiac allograft vasculopathy at 1, 5 and 10 years of 91.2%, 68.7% and 50.7%, respectively (compared with 98.3, 85.9 and 77.5 in our cohort). An explanation for this difference is complex but may be linked to the differences in the patients included as well as in the immunosuppressive regimen and cardiac allograft vasculopathy detection strategy. Considering the high rate of patients undergoing haemodialysis (10.4%), we suggest that creatinine clearance should be superior to 40 ml/min/1.73 m 2 when selecting older recipients to prevent significant morbidity linked to haemodialysis in this population. 
Evolution over 2 decades
Despite noteworthy progress in cardiac transplantation over time, our results showed no improvement in survival over the 2-decade period, unlike previous studies [2] . The second decade included a significant proportion of patients in critical condition due to the new graft allocation priority. Understandably, intensive care unit and hospital stays were longer in the second decade. Similarly, postoperative complications, such as renal replacement therapy and primary graft dysfunction, were more prevalent during this period. Moreover, donors were older in the second decade and had more cardiovascular risk factors. All of these factors contributed to the relative stagnation in survival from the first to the second decade, despite overall improvements in cardiac transplantation and immunosuppression. In our series, survival in the SE group was similar to that in the rest of the cohort. However, SE survival was lower in the rest of France during the same period compared with that in nonpriority listed patients. Moreover, long-term haemodialysis was more prevalent in the SE group explaining why since 2013, a creatinine clearance greater than 40 ml/min/1.73 m 2 has been required to apply for SE status. Since its appearance in France, this graft allocation priority enabled a significant reduction in mortality for those on the waiting list, reducing deaths from 307 to 231 per 1000 patient-years between 2004 and 2008 [12] . During this period, the donor heart shortage remained stable, with 2.2-2.3 candidates per graft.
Heart transplantation and mortality in the elderly
The main cause of death was malignancy in our population and survival in our population was highly impacted by non-skin solid tumours. Half of the malignancies were diagnosed <5 years after heart transplantation but systematic screening was not the rule. Thus, we recommend regular CT scans to enable the early diagnosis and treatment of malignancies. Long-term results after lung cancer surgery in heart transplant recipients are encouraging when the surgery is performed in the early stages [13] . This screening should be performed in combination with adequate immunosuppressive treatment with regular dermatological consultations and prostatic cancer screening. Notably, urological malignancies were more prevalent and are reported to be more aggressive than in the general population [14] . This systematic approach should reduce the occurrence of cancers and may improve long-term survival rates.
Limitations
One limitation of this study is its retrospective design. However, we had access to the medical archives of every patient included, which enabled this detailed and extensive analysis of outcomes.
Our cohort had fewer patients compared with international registries. However, our centres are located in the same geographic area and had similar protocols for patient selection and follow-up after heart transplantation. 
CONCLUSIONS
Our results confirm that older candidates should not be denied transplantation solely on the basis of age. Indeed, our 2-decade multicentre experience in France revealed that appropriate selection and rigorous follow-up of elderly recipients can lead to satisfying outcomes and survival rates using conventional donor hearts. Survival was slightly lower compared with that in younger patients and was highly impacted by malignancies that should require a systematic screening approach.
